Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with Rituximab

European Journal of Immunology

Volumn 38, Issue 1, 2008, Pages 292-298

  Ferraro, Alastair J ^a   Drayson, Mark T ^b   Savage, Caroline O S ^b   MacLennan, Ian C M ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Autoantibody; B cells; Inflammation; Plasma cells; Rituximab

Indexed keywords

ANTIGEN; AUTOANTIBODY; AZATHIOPRINE; CYCLOPHOSPHAMIDE; HEMAGGLUTININ; IMMUNOGLOBULIN G ANTIBODY; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOBLASTIN; PHOSPHORYLCHOLINE; PREDNISOLONE; RITUXIMAB;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CLINICAL ARTICLE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE DEPLETION; MONITORING; PLASMA CELL; PRIORITY JOURNAL; REMISSION; THYMUS; VASCULITIS;

ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIGENS, BACTERIAL; ANTIRHEUMATIC AGENTS; AUTOANTIBODIES; AUTOANTIGENS; B-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LYMPHOCYTE DEPLETION; SERINE ENDOPEPTIDASES; VASCULITIS;

EID: 38349056679     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200737557     Document Type: Article

References (50)

1. Reff, M. E., Carner, K., Chambers, K. S., Chinn, P. C., Leonard, J. E., Raab, R., Newman, R. A. et al., Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994. 83: 435-445.
2. Keogh, K. A., Ytterberg, S. R., Fervenza, F. C., Carlson, K. A., Schroeder, D. R. and Specks, U., Rituximab for refractory Wegener's granulomatosis. Report of a prospective, open label, pilot trial. Am. J. Respir. Crit. Care Med. 2006. 173: 180-187.
3. Edwards, J. C., Szczepanski, L., Szechinski, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M. and Shaw, T., Efficacy of B-cell- targeted therapy with Rituximab in patients with rheumatoid arthritis. N. Eng. J. Med. 2004. 350: 2572-2581.
4. Leandro, M. J., Edwards, J. C., Cambridge, G., Ehrenstein, M. R. and Isenberg, D. A., Art open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002. 46: 2673-2677.
5. Ferraro, A. J., Day, C. J., Drayson, M. T. and Savage, C. O., Effective therapeutic use of Rituximab in refractory Wegener's granulomatosis. Nephrol. Dial. Transplant. 2005. 20: 622-625.
6. Looney, R. J., Anolik, J. H., Campbell, D., Felgar, R. E., Young, F., Arend, L. J., Sloand, J. A. et al., B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/1I dose-escalation trial of Rituximab. Arthritis Rheum. 2004. 50: 2580-2589.
7. Cambridge, G., Leandro, M. J., Teodorescu, M., Manson, J., Rahman, A., Isenberg, D. A. and Edwards, J. C., B cell depletion therapy in systemic lupus erythematosus - Effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum. 2006. 54: 3612-3622.
8. Sibilia, J., Benlagha, K., Vanhille, P., Ronco, P., Brunet, J. C. and Marierte, X., Structural analysis of human antibodies to proteinase 3 from patients with Wegener granulomatosis. J. Immunol. 1997. 159: 712-719.
9. MacLennan, I. C. M., Germinal-centers. Annu. Rev. Immunol. 1994. 12: 117-139.
10. William, J., Euler, C., Christensen, S. and Shlomchik, M. J., Evolution of autoantibody responses via somatic hypermutation outside of germinal centers. Science 2002. 297: 2066-2070.
11. Weller, S., Faili, A., Garcia, C., Braun, M. C., Le Deist, F. F., Saint Basile, G. G., Hermine, O. et al., CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans. Proc. Nat. Acad. Sci. USA 2001. 98: 1166-1170.
12. Slifka, M. K., Antia, R., Whitmire, J. K. and Ahmed, R., Humoral immunity due to long-lived plasma cells. Immunity 1998. 8: 363-372.
13. Manz, R. A., Lohning, M., Cassese, G., Thiel, A. and Radbruch, A., Survival of long-lived plasma cells is independent of antigen. Int. Immunol. 1998. 10: 1703-1711.
14. Bienvenu, J., Whicher, J., Chir, B. and Aguzzi, F., Immunoglobulins.In Ritchie, R. F. and Navolotskaia, O. (Eds.) Serum proteins in clinical medicine. Foundation for Blood Research, Scarborough, ME 1996, pp 1-16.
15. Edwards, J. C. W., Cambridge, G. and Leandro, M. J., B cell depletion therapy in rheumatic disease. Best Pract. Res. Clin. Rheumatol. 2006. 20: 915-928.
16. Ho, F., Lortan, J. E., MacLennan, I. C. and Khan, M., Distinct short-lived and long-lived antibody-producing cell populations. Eur. J. Immunol. 1986. 16: 1297-1301.
17. Smith, K. G., Hewitson, T. D., Nossal, G. J. and Tarlinton, D. M., The phenotype and fate of the antibody-forming cells of the splenic foci. Eur. J. Immunol. 1996. 26: 444-448.
18. Hsu, M.-C., Toellner, K.-M., Vinuesa, C. G. and MacLennan, I. C. M., B cell clones that sustain long-term plasmablast growth in T-independent extrafollicular antibody responses. Proc. Nat. Acad. Sci. USA 2006. 103: 5905-5910.
19. Luqmani, R. A., Bacon, P. A., Moots, R. J., Janssen, B. A., Pall, A., Emery, P., Savage, C. and Adu, D., Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994. 87: 671-678.
20. Vieira, C. A., Agarwal, A., Book, B. K., Sidner, R. A., Bearden, C. M., Gebel, H. M., Roggero, A. L. et al., Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmaco-dynamics, and pharmacokinetics. Transplantation 2004. 77: 542-548.
21. Genberg, H., Hansson, A., Wernerson, A., Wennberg, L. and Tryden, G., Pharmacodynamics of Rituximab in kidney allotransplantation. Am. J. Transplant. 2006. 6: 2418-2428.
22. Cowan, M. J., Ammann, A. J., Wara, D. W., Howie, V. M., Schultz, L., Doyle, N. and Kaplan, M., Pneumococcal polysaccharide immunization in infants and children. Pediatrics 1978. 62: 721-727.
23. Konradsen, H. B., Quantity and avidity of pneumococcal antibodies before and up to 5 years after pneumococcal vaccination of elderly persons. Clin. Infect. Dis. 1995. 21: 616-620.
24. Naturally arising antibodies. In Mollison, P. L., Engelfriet, C. P. and Contreras, M. (Eds.) Blood transfusion in clinical medicine. Blackwell Scientific, London 1993, pp 100-102.
25. Gray, J. J., Avidity of EBV VCA-specific IgG antibodies: Distinction between recent primary infection, past infection and reactivation. J. Virol. Methods 1995. 52: 95-104.
26. Marchant, A., Pihlgren, M., Goetghebuer, T., Weiss, H. A., Ota, M. O. C., Schlegel-Hauter, S. E., The Medical Research Council Gambia Twin Study Group et al., Predominant influence of environmental determinants on the persistence and avidity maturation of antibody responses to vaccines in infants. J. Infect. Dis. 2006. 193: 1598-1605.
27. Schallert, N., Pihlgren, M., Kovarik, J., Roduit, C., Tougne, C., Bozzotti, P., Del Giudice, G. et al., Generation of adult-like antibody avidity profiles after early-life immunization with protein vaccines. Eur. J. Immunol. 2002. 32: 752-760.
28. Smith, K. G., Jones, R. B., Burns, S. M. and Jayne, D. R., Long-term comparison of Rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum. 2006. 54: 2970-2782.
29. Stasi, R., Stipa, E., Del Poeta, G., Amadori, S., Newland, A. C. and Provan, D., Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with Rituximab. Rheumatology 2006. 45: 1432-1436.
30. Cambridge, G., Stohl, W., Leandro, M. J., Migone, T.-S., Hilbert, D. M. and Edwards, J. C. W., Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following Rituximab treatment: Relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006. 54: 723-732.
31. Vallerskog, T., Gunnarsson, L, Widhe, M., Risselada, A., Klareskog, L., van Vollenhoven, R., Malmstrom, V. and Trollmo, C., Treatment with Rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin. Immunol. 2007. 122: 62-74.
32. Sze, D. M., Toellner, K. M., Garcia, D. V., Taylor, D. R. and MacLennan, I. C., Intrinsic constraint on plasmablast growth and extrinsic limits of plasma cell survival. J. Exp. Med. 2000. 192: 813-821.
33. Barth, W. F., Fahey, J. L., Waldmann, T. A. and Wochner, R. D., Metabolism of human gamma macroglobulins. J. Clin. Invest. 1964. 43: 1036-1048.
34. Paran, D., Trej'o, L. and Caspi, D., Clinical images: B cell depletion in the appendix following Rituximab treatment. Arthritis Rheum. 2006. 54: 2151.
35. Kneitz, C., Wilhelm, M. and Tony, H., Effective B cell depletion with Rituximab in the treatment of autoimmune diseases. Immunobiology 2002. 206: 519-527.
36. Vos, K., Thurlings, R. M., Wijbrandts, C. A., van Schaardenburg, D., Gerlag, D. M. and Tak, P. P., Early effects of Rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum. 2007. 56: 772-778.
37. van der Kolk, L. E., Baars, J. W., Prins, M. H. and van Oers, M. H. J., Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002. 100: 2257-2259.
38. Ramos, E. J., Pollinger, H. S., Stegall, M. D., Gloor, J. M., Dogan, A. and Grande, J. P., The effect of desensitization protocols on human splenic B-cell populations in vivo. Am. J. Transplant. 2007. 7: 402-407.
39. Gong, Q., On, Q., Ye, S., Lee, W. P., Cornelius, J., Diehl, L., Lin, W.Y. et al., Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 2005. 174: 817-826.
40. Baxendale, H. E., Davis, Z., White, H. N., Spellerberg, M. B., Stevenson, F. K. and Goldblatt, D., Immunogenetic analysis of the immune response to pneumococcal polysaccharide. Eur. J. Immunol. 2000. 30: 1214-1223.
41. Zhou, J., Lottenbach, K. R., Barenkarnp, S. J. and Reason, D. C., Somatic hypermutation and diverse immunoglobulin gene usage in the human antibody response to the capsular polysaccharide of Streptococcus pneumoniae type 6B. Infect. Immun. 2004. 72: 3505-3514.
42. Voswinkel, J., Mueller, A., Kraemer, J. A., Lamprecht, P., Herlyn, K., Holl-Ulrich, K., Feller, A. C. et al., B lymphocyte maturation in Wegener's granulomatosis: A comparative analysis of VH genes from endonasal lesions. Ann. Rheum. Dis. 2006. 65: 859-864.
43. Reparon-Schuijt, C. C., van Esch, W. J., van Kooten, C., Levarht, E. W., Breedveld, F. C. and Verweij, C. L., Functional analysis of rheumatoid factor-producing B cells from the synovial fluid of rheumatoid arthritis patients. Arthritis Rheum. 1998. 41: 2211-2220.
44. Hutloff, A., Buchner, K., Reiter, K., Baelde, H. J., Odendahl, M., Jacobi, A., Darner, T. and Kroczek, R. A., Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Arthritis Rheum. 2004. 50: 3211-3220.
45. Cassese, G., Lindenau, S., de Boer, B., Arce, S., Hauser, A., Riemekasten, G., Berek, C. et al., Inflamed kidneys of NZB/W mice are a major site for the homeostasis of plasma cells. Eur. J. Immunol. 2001. 31: 2726-2732.
46. Sekine, H., Watanabe, H. and Gilkeson, G. S., Enrichment of anti-glomerular antigen antibody-producing cells in the kidneys of MRL/ MpJ-Fas(Ipr) mice. J. Immunol. 2004. 172: 3913-3921.
47. Tsubaki, T., Takegawa, S., Hanamoto, H., Arita, N., Kamogawa, J., Yamamoto, H., Takubo, N. et al., Accumulation of plasma cells expressing CXCR3 in the synovial sublining regions of early rheumatoid arthritis in association with production of Mig/CXCL9 by synovial fibroblasts. Clin. Exp. Immunol. 2005. 141: 363-371.
48. van Oosterhout, M., Levarht, E. W., Sont, J. K., Huizinga, T. W., Toes, R. E. and van Laar, J. M., Clinical efficacy of infliximab plus methatrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12. Ann. Rheum. Dis. 2005. 64: 537-543.
49. Leavitt, R. Y., Fauci, A. S., Bloch, D. A., Michel, B. A., Hunder, G. G., Arend, W. P., Calabrese, L. H. et al., The American College of Rheumatology 1990 criteria for the classification of Wegener granulomatosis. Arthritis Rheum. 1990. 33: 1101-1107.
50. Lal, G., Balmer, P., Stanford, E., Martin, S., Warrington, R. and Borrow, R., Development and validation of a nonaplex assay for the simultaneous quantitation of antibodies to nine Streptococcus pneumoniae serotypes. J. Immunol. Methods 2005. 296: 135-147.